Aktienanalyse zu Benitec Biopharma Inc (BNTC)BNTCBenitec Biopharma Inc

Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Benitec Biopharma Inc (BNTC) is not a good buy right now due to its current price of $8.49, which is significantly below its 52-week high of $15.86, indicating a 46.5% potential upside if it reaches that level. However, the stock has a low RSI of 39.12, suggesting it is nearing oversold conditions, but the forward P/E ratio is 0, indicating no expected earnings in the near term. The company also reported a net loss of $12.81 million in the latest quarter, raising concerns about its financial stability.

1 analysts cover BNTC: 0 rate it Buy, 1 Hold and 0 Sell. The average price target is 32.00.